The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Well the SP was pretty stable from Aug through Jan before the 3rd drawdown so makes no sense, but either way they are gone now still don't think it was the worst option at least we were funded for P1b and weren't diluted further....
Not volume as such. You cannot use the drawdown facility at more than 1 million debt balance. The amount owing with drawdown cannot be greater than 10% of market cap.
Manipulated to create financial chaos.
I should think they looked at the detail in the small print am sure even Stevie Wonder could have found it.
Regards
Not volume as such. You cannot use the drawdown facility at more than 1 million debt balance. The amount owing with drawdown cannot be greater than 10% of market cap.
Manipulated to create financial chaos.
I should think they looked at the detail in the small print am sure even Stevie Wonder could have found it.
Regards
Pot not defending the Bod and they should of raised on previous highs for P1a / P1b but possible it was the only option available at the time, didn't the RF deal fail because of low volume which was just market sentiment....
I think SOG should be appointed to the BOD without delay in order to represent shareholders interests! :-) That way these financial co*ck up's should not happen again!
Sareum have 3 advisors.
Broker 1 - Hybridan - They do our reports, broker notes etc. I think we oat them £60k a year.
Broker 2 - Peel Hunt - if we are to believe the board, PH were engaged to market Sareum to institution investors. To do that, the company needs to be stable, investable and a, safe ish pair of hands. IMO, PH will have recommended the consolidation, because over 3 billions shares in issue make you look like a penny stock. Ironically, that where Sareum find themselves again.
Nomad - Strand Hanson are the Nominated and Financial Advisors. They would have looked at this RF and advised on it but at the end of the day, the buck stops at Parker and the board. It looks like zero due diligence was done. 10 minutes on Google and lse chats boards would have told them RF were bad news.
I dont want a witch hunt but I also dont get why we give the board a free ride here. Their decisions nearly finished the company.
It's done now but we, the shareholders must never let it happen again.
''We deserve to be informed by the BOD who it was who suggested RF and who knew their form''.
We certainly do fearg (and my money's on Parker and 'Real C**t' in that order, but all in my own opinion of course!) but whether we will though is a different matter!?!
Still news is due soon (hopefully good) and the sp certainly appears to be moving in the right direction (for now!).
Excellent scientific and financial analysis SOG. We are back in the race again despite the mugging along the way. Its been a bare knukle ride and we have survived it. I think that the scientific expertise shared on this board by you and some others has helped greatly to give the confidence needed to stay invested in this company.
Good evening fearg,
Similar opinions as myself, definate downward pressure by RF to to put financial destruction on Sareum. From the RNS of today the rerate has begun.
RF can sell what they like. Hence gradual grind over 6 months,from Aug to Feb (105p to 60p ) and then from Feb to March dropped 60p to 10p.
Another raise and shares may have been manipulated down to less than a penny. RF come along kindly help with more peanut finance and acquire Sareum. Sold in the hundreds of millions later!
Share price was 105p prior to RF involvement.
Circa 70 million shares at that time, now around 105 so approx 50% dilution.
So realistically we are looking at 70p per share to bring the SP or to be more precise the Market Cap of 70 million.
Now 1801 has advanced since, as we now await safety data results that we expect to enable us to traverse into a company that has a phase 2 asset.
In addition we await news of the licensee that has taken on 737 a checkpoint 1 kinase inhibitor.
Checkpoint kinase inhibitors are effective at what they are designed to do, but to satisfy the demands of regulating authorities such as the NDA they need to be used in combination therapy satisfactorily to gain clinical use authorisations.
With regards to 1801 that will also have a knock on effect to 1802.
I would suggest that on satisfactory 1801 news we can expect a minimum 50% to 100% rise. On commencement of phase 2a trial (that may require raising of funds to bring the Mcap to around 150 to 175 million.
News on 737 maybe 5 to 7.5 million as a rough guide.
155 to 180 million market cap
Approx 150p to 180p per share.
On licence will depend on phase 2 data.
End of phase 2 as l have put before an upfront payment of between 200 and 400 million and with good Indications outside of psoriasis maybe up to 800 million.
No Jaki inhibitors irrelevant of selectivity have ever been authorised for clinical use without the dreaded black box warnings.
Allosteric TYK2 Deucravacitinib)has proven so far excellent with regards to safety albeit the efficacy on Psoriasis is adequate, it is believed by using the dual inhibition approach of Tyk2 and Jak1 that this would yield superior efficacy over Tyk2 alone. 1801 is Tyk 2 Jak1 an oral formulation that has the added underestimated benefit of being administered in a capsule formulation.
The safety profile of SDC-1801 if comparable to Deucravacitinib would make us available for clinical use without the dreaded black box warnings and a greater efficacy in certain Indications.
Let's face it Deucravacitinib flunked badly in UC.
This all new allosteric Tyk2 inhibitor that regulates the active domain via the pseudo domain?
How much would 1801 be worth with a safety profile comparable with Deucracitinib but better efficacy?
Mind blowing!
Regards
Cobalt
Yes so I suggest metaphorically 😂😂
Do you know what a Warthog looks like?🤣🤣
Warty
He wasn’t being nasty.. you two should kiss and make up 🙄
Aha! I see a filtered message! Must be CBlue having one of his periodic outbursts of vitreol!
I would expect that this is the beginning of the rerate rather than the beginning of the end with plenty more news to come. On thing is certain and that there is never certainty, but the omens are positive.
We have been through the mill on this and I believe the trap door was being prepared. I think the forces of darkness thought that with the sp on the floor and funding withdrawn, probably as planned, that SAR would fail. Perhaps a share price of aprox 2p was being prepared for the investors on a take it or leave it basis, after which the company would go private and be set up, after the completion of P1a, to be flogged at a massive markup to a pharma.
We deserve to be informed by the BOD who it was who suggested RF and who knew their form. It must have been well known as Puma was telling us all about how it would pan out. Without shareholder participation it is unclear whether we could have survived.
We need to know for the simple reason that how can we be sure thatsuch a scenario won't be hoisted on us again in the future.
Issues like consolidation were imposed on us with no regard for the views of the owners of this company, the shareholders.
I believe that the BOD, while negligent, they did shape up when heel come to shove in organising the recent funding arrangement.
I'm about the same warthog I tend not to look to much when it's rising , I certainly can't call this one I thought RF was priced in.....
That's because you're such a pessimist.
.. total credit for the rapid rise to today's closing!
I am the kiss of death when it comes to dealing. Bearing in mind Sareum's SP volatility I sold my Wrap, albeit for a tidy tickle, since which time the SP has forged ahead. Shudder to think what would happen if I put my toe in the water again tomorrow.